Genelux (NASDAQ:GNLX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen lowered shares of Genelux (NASDAQ:GNLX) from a hold rating to a sell rating in a research report released on Sunday morning.

GNLX has been the subject of a number of other reports. Lake Street Capital began coverage on shares of Genelux in a research report on Tuesday, October 21st. They set a “buy” rating and a $16.00 target price for the company. Loop Capital set a $16.00 price objective on Genelux in a research note on Tuesday, October 21st. Maxim Group set a $20.00 price objective on Genelux in a report on Tuesday, October 21st. Weiss Ratings reissued a “sell (e+)” rating on shares of Genelux in a research report on Wednesday, October 8th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Genelux in a research report on Monday, January 5th. Three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $21.00.

Genelux Price Performance

NASDAQ GNLX opened at $2.80 on Friday. The stock has a market capitalization of $106.54 million, a price-to-earnings ratio of -3.18 and a beta of 0.17. Genelux has a one year low of $1.99 and a one year high of $8.53. The business’s fifty day moving average is $4.83 and its 200-day moving average is $4.39.

Genelux (NASDAQ:GNLX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.02. Research analysts expect that Genelux will post -0.88 EPS for the current fiscal year.

Insider Transactions at Genelux

In other Genelux news, Director John Thomas sold 10,000 shares of the stock in a transaction on Monday, December 1st. The stock was sold at an average price of $5.00, for a total transaction of $50,000.00. Following the sale, the director owned 492,784 shares in the company, valued at $2,463,920. This represents a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Over the last quarter, insiders have sold 15,990 shares of company stock worth $82,054. Insiders own 8.80% of the company’s stock.

Hedge Funds Weigh In On Genelux

Several hedge funds have recently made changes to their positions in the stock. Goldman Sachs Group Inc. purchased a new stake in Genelux during the 1st quarter worth about $239,000. Jane Street Group LLC bought a new stake in shares of Genelux during the first quarter valued at about $190,000. Integrity Alliance LLC. bought a new stake in shares of Genelux during the first quarter valued at about $84,000. Falcon Wealth Planning lifted its holdings in shares of Genelux by 83.3% in the second quarter. Falcon Wealth Planning now owns 22,000 shares of the company’s stock worth $63,000 after buying an additional 10,000 shares in the last quarter. Finally, Beacon Capital Management LLC boosted its position in shares of Genelux by 99.8% in the second quarter. Beacon Capital Management LLC now owns 19,116 shares of the company’s stock valued at $55,000 after acquiring an additional 9,550 shares during the period. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.